

Melody Cobleigh, MD.

Professor

Internal Medicine, Hematology, Oncology and Cell Therapy
Rush Medical College
Rush University

CONTACT INFORMATION

melody_cobleigh@rush.edu

EDUCATION

Degrees

MD, Rush Medical College of Rush University Medical Center 1972 - 1976
BA, Northeastern University 1967 - 1970

Postgraduate

Fellowship, Indiana University School of Medicine, Medical Oncology 1979 - 1981
Postdoctoral Fellowship, Rush University Medical Center, Immunology/ Oncology 1979
Residency, Rush University Medical Center, Internal Medicine 1977 - 1979
Internship, Rush University Medical Center, Internal Medicine 1976 - 1977

ACADEMIC APPOINTMENTS

Professor, Internal Medicine, Hematology, Oncology and Cell Therapy, Rush Medical College, Rush University 1999 - Present
Associate Professor, Internal Medicine, Hematology, Oncology and Cell Therapy, Rush Medical College, Rush University 1989 - 1999

NON-RUSH ACADEMIC APPOINTMENTS

Associate Professor, University of Illinois 1987 - 1989
Assistant Professor, University of Illinois 1981 - 1987

ADMINISTRATIVE TITLES

Section Chief, Rush Medical College, Internal Medicine, Hematology, Oncology and Cell Therapy, Oncology 1900 - 2020

CERTIFICATION AND LICENSURE

DEA Number, AC1236214, United States Drug Enforcement Administration 2021
Illinois Controlled Substances Number (ILCS), 336-018825, State of Illinois 2020
Medical License, 036-054142, State of Illinois 2020

BOARD/SPECIALTY

Primary Specialty (Medical Oncology)
American Board of Internal Medicine (Medical Oncology), Lifetime Certification 1981 - Present
American Board of Internal Medicine (Internal Medicine), Lifetime Certification 1979 - Present

HOSPITAL PRIVILEGES

Rush Oak Park Hospital 2009 - Present
Rush University Medical Center, Chicago, IL 1989 - Present

HONORS AND AWARDS

Best doctors for serious illnesses, Chicago Magazine 2020
As voted by peers
Best doctors, Chicago Magazine 2020
As voted by peers
Forbes Magazine: Best breast cancer doctors in America 2018
Newsweek 2015
Brian Piccolo Chair for Cancer Research 2013
Chicago Magazine - Women's Health 2011

Distinguished Alumni Award, Rush Medical College	2001
Maria Albanese Endowed Chair in Breast Cancer Research	2001
Department of Internal Medicine Teaching and Service Award, Rush-Presbyterian St. Luke's Medical Center	1990
Resident of the Year Award, Rush-Presbyterian St. Luke's Medical Center	1978
Alpha Omega Alpha Honors Medical Society	1976
Honors, Northeastern Illinois University	1970

SOCIETY MEMBERSHIPS

American Federation for Clinical Research	1985 - 1989
American Association for Cancer Research	1983 - 2005
American Society of Clinical Oncology	1981 - Present
Alpha Omega Alpha Honor Medical Society	1976 - Present

CLINICAL EXCELLENCE

Clinical Innovations

OncotypeDx assay, Used routinely in clinical practice	1995 - Present
Genomic assay to identify breast cancer patients who need chemotherapy. Assay is now part of ASCO Guidelines	

Clinical Practice

RVU. RUMC & ROPH	2019 - 2020
Exceeded RVU target.	
Exceeded patient satisfaction target.	
Named in Chicago Magazine Top Doctors, Jan 2020.	

Clinical Research/Clinical Trials

Abstract Chair, Phase III Randomized controlled clinical trial of radiation with or without trastuzumab in HER2+ DCIS resected by lumpectomy, Chair clinical trial, Number of Patients: 8000	2008 - 2019
Designed, wrote and conducted international clinical trial. Oral presentation at ASCO 2020.	

COMMITTEE AND ADMINISTRATIVE SERVICE

International

Active Member, Committee member, Protocol chair, PI, NRG Oncology, Time Commitment: 25 hrs/year	2013 - 2018
Attend NRG meetings twice annually.	
Review new protocols for NRG-Breast before activation	
Attend NSABP foundation meetings twice annually.	
Serve as principle investigator for NRG and NSABP Foundation trials conducted at Rush.	
Review thousands of external adverse event reports.	
Serve as international PI for NSABP/NRG B43 protocol	
Champion involvement of new faculty in NRG/NSABP	

Institutional

Active Member, Co-chair of breast cancer program, Rush Cancer center, Time Commitment: 0.1 cFTE	2017 - 2019
Organized breast cancer program for Rush	

SCIENTIFIC AND SCHOLARLY ACTIVITIES

Patents

Methof of Treatment Utilizing a Gene Expression Signature Predicting the Response of HER2-Directed Therapies, Status: Submitted, PCT/US19/23562	03-22-2019
Gene expression Markers for Breast Cancer Prognosis, Status: Awarded, US Patent 9,944990	04-17-2018
METHODS FOR TREATING A DISEASE OR CONDITION IN A SUBJECT, Status: Submitted Application 62/507,867	05-19-2017
Method of Treatment Utilizing a Gene Expression Signature Predicting the Response of HER2-Directed Therapies, Status: Submitted Application 62/466,675	03-08-2017
Targeted Small Molecule Inhibitors in Mutant NF-1 Containing Breast Cancers, Status: Submitted Application 62/437,909	12-27-2016
Gene expression Markers for Breast Cancer Prognosis, Status: Submitted, US Patent 8,206,919	06-26-2012

Invited Presentations at Regional, National, and International Meetings

Invited Speaker, Cobleigh, MA et al. Randomized phase III trial of radiation with or without trastuzumab in HER2-positive DCIS resected by lumpectomy. Virtual. 05-30-2020
Oral presentation at ASCO

FUNDING HISTORY

Federal

Pending

Department of Defense. **Cobleigh**, Co-Investigator "Next Generation Sequencing of Isogenic Cells Reveals a Predictive Signature of Trastuzumab Resistance". 10-01-2015 - 09-30-2016.

Foundation

Awarded

Bears Care. **Cobleigh**, Principal Investigator "To support one of the 2017 grants from Bears Care awarded to". 01-31-2017 - 01-31-2019.

Daniel and Ada Rice Foundation. **Cobleigh**, Principal Investigator "Research to Identify Tumor-Specific Genetic Alterations in". 01-01-2015 - 06-30-2035.

Pink Pumpkin Patch Foundation. **Cobleigh**, Principal Investigator "Breast Cancer Research Grant". 04-01-2014 - 06-30-2035.

Sherman Fairchild Foundation. **Cobleigh**, Principal Investigator "Breast Cancer Research". 08-01-2010 - 06-30-2035.

Clinical Trial

Awarded

ECOG Coordinating Center EA1181. **Cobleigh**, Principal Investigator "Preoperative THP and postoperative de-escalation". 02-11-2020 - 06-30-2035.

NRG Oncology NRG-BR004. **Cobleigh**, Principal Investigator "NRG-GY018: A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY OF". 03-12-2019 - 06-30-2035.

NCTN/SWOG S1418. **Cobleigh**, Principal Investigator "A Randomized, Phase III trial to Evaluate the Efficacy and". 11-15-2016 - 06-30-2035.

NRG Oncology. **Cobleigh**, Principal Investigator "Exceptional Responders Pilot Study: Molecular Profiling". 05-24-2016 - 06-30-2035.

NRG Oncology NSABP-B-55. **Cobleigh**, Principal Investigator "A Randomized, Double-Blind, Parallel Group, Placebo-". 07-03-2014 - 06-30-2035.

NSABP Foundation Inc. B-43. **Cobleigh**, Principal Investigator "A Phase II Clinical Trial Comparing Trastuzumab Given". 10-09-2008 - 09-30-2015.

NSABP Foundation Inc.. **Cobleigh**, Principal Investigator "NSABP Found Inc.". 07-01-1995 - 06-30-2035.

Industry

Awarded

SYNEOS HEALTH LLC. **Cobleigh**, Principal Investigator "A Phase 2, Multiarm, Multicenter, Open-label Study to". 04-15-2020 - 06-30-2035.

Cobleigh, Principal Investigator "SGNTUC-016: Randomized, double-blind, phase 3 study of". 04-14-2020 - 06-30-2035.

Cobleigh, Principal Investigator "NRG-BR004: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF". 03-12-2019 - 06-30-2035.

RADIUS HEALTH INC. **Cobleigh**, Principal Investigator "EMERALD: Elacestrant monotherapy vs. standard of care for". 05-13-2019 - 06-30-2035.

INC RESEARCH, LLC. **Cobleigh**, Principal Investigator "Phase 1 Trial of ZW25 in patients with locally advanced". 03-04-2018 - 06-30-2035.

NSABP Foundation Inc.. **Cobleigh**, Principal Investigator "NSABP B-59-I: A randomized, double-blind, phase 3 clinical". 02-09-2018 - 06-30-2035.

INC RESEARCH, LLC. **Cobleigh**, Principal Investigator "A multi-centre, open-label, randomized clinical trial". 02-26-2018 - 06-30-2035.

NCTN/SWOG. **Cobleigh**, Principal Investigator "SWOG_1418/BR006: Phase 3 trial to evaluate the efficacy &". 11-15-2016 - 06-30-2035.

Seattle Genetics, Inc. **Cobleigh**, Principal Investigator "ONT-380-206". 04-01-2016 - 06-30-2035.

NSABP Foundation Inc. B-57-I. **Cobleigh**, Principal Investigator "A Randomized Phase III Trial of Palbociclib with Standard". 06-28-2016 - 06-30-2035.

Genentech. **Cobleigh**, Principal Investigator "An In-Clinic Survey and Chart Review of Women Living". 01-14-2015 - 06-30-2035.

NSABP Foundation Inc.. **Cobleigh**, Principal Investigator "Phase III Study Evaluating Palbociclib (pD-0332991), a". 04-01-2015 - 06-30-2035.

MacroGenics, Inc.. **Cobleigh**, Principal Investigator "A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy". 10-15-2015 - 06-30-2035.

Merrimack Pharmaceuticals. **Cobleigh**, Principal Investigator "Protocol MM-302-02-02-03". 08-01-2015 - 06-30-2035.

NRG Oncology. **Cobleigh**, Principal Investigator "A Randomized, Double-Blind, Parallel Group, Placebo-Controll". 07-03-2014 - 06-30-2035.

Hoffman LaRoche - National. **Cobleigh**, Principal Investigator "Procotol Nsabp B-50". 03-01-2014 - 06-30-2035.

Genentech, Inc. **Cobleigh**, Principal Investigator "Systhers Registry - An Oberservational Study in Patients". 07-01-2014 - 06-30-2035.

Genentech. **Cobleigh**, Principal Investigator "A Randomized, Phase II, Multicenter, Placebo Controlled". 10-01-2014 - 06-30-2035.

Washington University - Nation. **Cobleigh**, Principal Investigator "Protocol 201209135". 08-01-2013 - 06-30-2035.

Genentech. **Cobleigh**, Principal Investigator "Protocol Tdm4997G". 06-01-2012 - 06-30-2035.

Genentech. **Cobleigh**, Principal Investigator "Protocol Tdm4884G". 05-17-2010 - 04-19-2014.

Genentech. **Cobleigh**, Principal Investigator "Protocol Tdm4370G". 07-01-2009 - 06-30-2035.

Genentech. **Cobleigh**, Principal Investigator "Protocol Tdm4450G". 06-01-2009 - 12-19-2012.

BIBLIOGRAPHY h-index=36(Scopus);

Journal Articles

1. DiScala M, Najor MS, Yung T, Morgan D, Abukhdeir AM, **Cobleigh MA**. Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. *PLoS ONE*. 2020;15doi:10.1371/journal.pone.0234146 PMID: 32525891
2. Prabhu N, Patel H, Golemi L, Fogg L, Cobleigh M, Okwuosa T. Trastuzumab-induced cardiac toxicity: Is serial assessment of left ventricular ejection fraction during treatment necessary?. *Breast Journal*. 2020;261085-1086. doi:10.1111/tbj.13672 PMID: 31674100
3. Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. Baseline characteristics, treatment patterns, and outcomes in patients with HER2-positive metastatic breast cancer by hormone receptor status from systhers. *Clinical Cancer Research*. 2020;261105-1113. doi:10.1158/1078-0432.CCR-19-2350 PMID: 31772121
4. Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. *Oncologist*. 2020;25e214-e222. doi:10.1634/theoncologist.2019-0446 PMID: 31611330
5. Elliott E, Speare V, Coggan J, Espenschied C, LaDuca H, Yussuf AF, Burgess K, Gray P, Cobleigh M, Rao R, Patel J, Kuzel T, Buckingham LE, Usha L. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. *Cancer Reports*. 2020;doi:10.1002/cnr2.1287 PMID: None
6. Turturro SB, Najor MS, Yung T, Portt L, Malarkey CS, Abukhdeir AM, **Cobleigh MA**. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. *Breast Cancer Research and Treatment*. 2019;177325-333. doi:10.1007/s10549-019-05320-x PMID: 31209687
7. Buckingham L, Mitchell R, Maienschein-Cline M, Green S, Hu VH, Cobleigh M, Rotmensch J, Burgess K, Usha L. Somatic variants of potential clinical significance in the tumors of BRCA phenocopies. *Hereditary Cancer in Clinical Practice*. 2019;17doi:10.1186/s13053-019-0117-5 PMID: None
8. Shammo JM, Usha L, Richardson KJ, Elliott E, Dewdney S, Venugopal P, Cobleigh M, Kuzel TM. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. *Journal of oncology practice*. 2019;15405-407. doi:10.1200/JOP.18.00705 PMID: 31199709
9. Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: Patient characteristics, treatment, and survival from systhers. *Clinical Cancer Research*. 2019;252433-2441. doi:10.1158/1078-0432.CCR-18-2366 PMID: 30593513
10. Mitchell R, Buckingham L, Cobleigh M, Rotmensch J, Burgess K, Usha L. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?. *PLoS ONE*. 2018;13doi:10.1371/journal.pone.0195497 PMID: 29659587
11. Njoroge SW, Burgess KR, **Cobleigh MA**, Alnajjar HH, Gattuso P, Usha L. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. *Breast Cancer Research and Treatment*. 2017;166315-319. doi:10.1007/s10549-017-4393-3 PMID: 28702897
12. Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson

- J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. *Clinical Cancer Research*. 2017;235687-5695. doi:10.1158/1078-0432.CCR-17-0900 PMID: 28679771
13. Maslyar DJ, Espi M, Espi M, Blau S, Blau S, Tan AR, Isakoff SJ, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Baselga J, Kim SB, Lee KS, Im SA, Wang HC, Dent R, Tan A, Sohn JH, De Laurentiis M, Estevez LG, Huang CS, Romieu G, Velez M, Villanueva R, Conte PF, Dakhil S, Debled M, Martin AG, Hurvitz S, Kim JH, Levy C, Oliveira M, Rovira PS, Seo JH, Valero V, Vidal G, Wong A, Allison MAK, Figlin R, Chan D, Chen SC, Chen YH, Cobleigh M, De Braud F, Dirix L, Hansen V, Bessard AH, Iannotti N, Isakoff S, Lawler W, Montao A, Salkini M, Seigel L. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet Oncology*. 2017;181360-1372. doi:10.1016/S1470-2045(17)30450-3 PMID: 28800861
 14. Brann AM, **Cobleigh MA**, Okwuosa TM. Cardiovascular monitoring with trastuzumab therapy: How frequent is too frequent?. *JAMA Oncology*. 2016;21123-1124. doi:10.1001/jamaoncol.2016.1288 PMID: 27280310
 15. Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. *Annals of Oncology*. 2016;271029-1034. doi:10.1093/annonc/mdw132 PMID: 26961151
 16. Turturro SB, Najor MS, Ruby CE, **Cobleigh MA**, Abukhdeir AM. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. *Breast Cancer Research and Treatment*. 2016;15633-43. doi:10.1007/s10549-016-3729-8 PMID: 26915040
 17. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. *British Journal of Cancer*. 2014;1111241-1248. doi:10.1038/bjc.2014.430 PMID: 25117820
 18. Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin JY. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: Clinical implications of the effect of covariates. *Cancer Chemotherapy and Pharmacology*. 2014;74399-410. doi:10.1007/s00280-014-2500-2 PMID: 24939213
 19. Siziopikou KP, Anderson SJ, **Cobleigh MA**, Julian TB, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Eakle JF, Leasure NC, Atkins JN, Polikoff JA, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Costantino JP, Wolmark N. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. *Breast Cancer Research and Treatment*. 2013;142415-421. doi:10.1007/s10549-013-2755-z PMID: 24202240
 20. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, **Cobleigh MA**, Perez EA, Shenkier TN, Nielsen KV, Miller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; Results from ECOG 2100 trial. *Clinical Cancer Research*. 2013;191281-1289. doi:10.1158/1078-0432.CCR-12-3029 PMID: 23340303
 21. Rao R, Cobleigh M. HER2-directed treatment of metastatic breast cancer: Unanswered questions. *ONCOLOGY (United States)*. 2013;27 PMID: 23687785
 22. Rao RD, **Cobleigh MA**. Adjuvant endocrine therapy for breast cancer. *ONCOLOGY (United States)*. 2012;26 PMID: 22870539
 23. Rao RD, **Cobleigh MA**, Gray R, Graham ML, Norton L, Martino S, Budd GT, Ingle JN, Wood WC. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs.

- tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): An intergroup trial coordinated by the Eastern Cooperative Oncology Group. *Medical Oncology*. 2011;28doi:10.1007/s12032-010-9682-1 PMID: None
24. **Cobleigh MA**. Other options in the treatment of advanced breast cancer. *Seminars in Oncology*. 2011;38doi:10.1053/j.seminoncol.2011.04.005 PMID: 21600380
 25. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, **Cobleigh MA**, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. *Clinical Cancer Research*. 2011;17372-381. doi:10.1158/1078-0432.CCR-10-1791 PMID: 21224365
 26. Julian TB, **Cobleigh MA**, Siziopikou KP. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. *Breast Diseases*. 2011;22282-283. doi:10.1016/j.breastdis.2011.06.012 PMID: None
 27. Dickler MN, **Cobleigh MA**, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. *Breast Cancer Research and Treatment*. 2009;115115-121. doi:10.1007/s10549-008-0055-9 PMID: 18496750
 28. Taylor ME, Haffty BG, Rabinovitch R, Arthur DW, Halberg FE, Strom EA, White JR, **Cobleigh MA**, Edge SB. ACR Appropriateness Criteria on Postmastectomy Radiotherapy. Expert Panel on Radiation Oncology-Breast. *International Journal of Radiation Oncology Biology Physics*. 2009;73997-1002. doi:10.1016/j.ijrobp.2008.10.080 PMID: 19251087
 29. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. *Journal of Clinical Oncology*. 2008;264672-4678. doi:10.1200/JCO.2008.16.1612 PMID: 18824714
 30. Burstein HJ, Elias AD, Rugo HS, **Cobleigh MA**, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *Journal of Clinical Oncology*. 2008;261810-1816. doi:10.1200/JCO.2007.14.5375 PMID: 18347007
 31. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *New England Journal of Medicine*. 2007;3572666-2676. doi:10.1056/NEJMoa072113 PMID: None
 32. Moore S, **Cobleigh MA**. Targeting Metastatic and Advanced Breast Cancer. *Seminars in Oncology Nursing*. 2007;2337-45. doi:10.1016/j.soncn.2006.11.007 PMID: 17303515
 33. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. *Breast*. 2007;16104-107. doi:10.1016/j.breast.2006.09.003 PMID: 17097880
 34. Oleske DM, Galvez A, **Cobleigh MA**, Ganschow P, Ayala LD. Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial. *Breast Journal*. 2007;1319-27. doi:10.1111/j.1524-4741.2006.00358.x PMID: 17214789
 35. Siziopikou KP, Ariga R, Prousaloglou KE, Gattuso P, Cobleigh M. The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: A promising candidate for epidermal growth factor receptor-targeted therapy?. *Breast Journal*. 2006;12360-362. doi:10.1111/j.1075-122X.2006.00276.x PMID: 16848847
 36. Robert N, Leyland-Jones B, Asmar L, Belt R, Llegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 - Overexpressing metastatic breast cancer. *Journal of Clinical Oncology*. 2006;242786-2792.

- doi:10.1200/JCO.2005.04.1764 PMID: 16782917
37. **Cobleigh MA**, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. *Clinical Cancer Research*. 2005;118623-8631. doi:10.1158/1078-0432.CCR-05-0735 PMID: 16361546
 38. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI. Genetic testing in an ethnically diverse cohort of high-risk women: A comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. *Journal of the American Medical Association*. 2005;2941925-1933. doi:10.1001/jama.294.15.1925 PMID: 16234499
 39. Mass RD, Press MF, Anderson S, **Cobleigh MA**, Vogel CL, Dybdal N, Leiberman G, Slamon DJ, Paton VE. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. *Clinical Breast Cancer*. 2005;6240-246. doi:10.3816/CBC.2005.n.026 PMID: 16137435
 40. Miller KD, Chap LI, Holmes FA, **Cobleigh MA**, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *Journal of Clinical Oncology*. 2005;23792-799. doi:10.1200/JCO.2005.05.098 PMID: 15681523
 41. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, **Cobleigh MA**, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. *Journal of Clinical Oncology*. 2005;23619-629. doi:10.1200/JCO.2005.09.121 PMID: 15545664
 42. Oleske DM, **Cobleigh MA**, Phillips M, Nachman KL. Determination of factors associated with hospitalization in breast cancer survivors.. *Oncology nursing forum*. 2004;311081-1088. doi:10.1188/04.ONF.1081-1088 PMID: 15547631
 43. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, **Cobleigh MA**, Galbraith S, Sledge GW. A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer. *Clinical Cancer Research*. 2004;101971-1975. doi:10.1158/1078-0432.CCR-03-0968 PMID: 15041714
 44. Cobleigh M, Somberg JC. A case of herceptin cardiotoxicity.. *American journal of therapeutics*. 2004;1174-76. doi:10.1097/00045391-200401000-00013 PMID: 14704598
 45. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. *Journal of Clinical Oncology*. 2004;221063-1070. doi:10.1200/JCO.2004.06.557 PMID: 15020607
 46. Cobleigh M, Frame D. Is trastuzumab every three weeks ready for prime time?. *Journal of Clinical Oncology*. 2003;213900-3901. doi:10.1200/JCO.2003.07.984 PMID: 14507945
 47. **Cobleigh MA**, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A. A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer. *Seminars in Oncology*. 2003;30117-124. doi:10.1053/j.seminoncol.2003.08.013 PMID: 14613032
 48. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, **Cobleigh MA**, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: Use of aromatase inhibitors in the adjuvant setting. *Journal of Clinical Oncology*. 2003;212597-2599. doi:10.1200/JCO.2003.04.596 PMID: 12732612
 49. Orucevic A, Reddy VB, Bloom KJ, Bitterman P, Magi-Galluzzi C, Oleske DM, Phillips M, Gould VE, Cobleigh M, Wick MR, Gattuso P. Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. *Breast Journal*. 2002;8349-355. doi:10.1046/j.1524-4741.2002.08604.x

- PMID: 12390357
50. Miller KD, Gradishar W, Schuchter L, Sparano JA, Cobleigh M, Robert N, Rasmussen H, Sledge GW. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. *Annals of Oncology*. 2002;131220-1224. doi:10.1093/annonc/mdf199 PMID: 12181245
 51. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, **Cobleigh MA**, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. *Journal of Clinical Oncology*. 2002;203317-3327. doi:10.1200/JCO.2002.06.020 PMID: 12149306
 52. Vogel CL, **Cobleigh MA**, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *Journal of Clinical Oncology*. 2002;20719-726. doi:10.1200/JCO.20.3.719 PMID: 11821453
 53. Tangney CC, Young JA, Murtaugh MA, **Cobleigh MA**, Oleske DM. Self-reported dietary habits, overall dietary quality and symptomatology of breast cancer survivors: A cross-sectional examination. *Breast Cancer Research and Treatment*. 2002;71113-123. doi:10.1023/A:1013885508755 PMID: 11881909
 54. **Cobleigh MA**, Miller KD, Langmuir VK, Reimann JD, Vassel AV, Novotny WF, Sledge GW. Phase II dose escalation trial of Avastin (bevacizumab) in women with previously treated metastatic breast cancer. *Breast Cancer Research and Treatment*. 2001;69301. PMID: None
 55. Mass R, Cobleigh M, Vogel C, Slamon D. Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit. *Breast Cancer Research and Treatment*. 2001;69302. PMID: None
 56. Vogel C, **Cobleigh MA**, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: A preliminary report. *European Journal of Cancer*. 2001;3725-29. doi:10.1016/S0959-8049(00)00405-6 PMID: 11167088
 57. Vogel CL, **Cobleigh MA**, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line herceptin monotherapy in metastatic breast cancer. *Oncology*. 2001;6137-42. doi:10.1159/000055400 PMID: 11694786
 58. **Cobleigh MA**. Managing menopausal problems.. *Cancer treatment and research*. 2000;1031-23. doi:10.1007/978-1-4757-3147-7_1 PMID: 10948439
 59. **Cobleigh MA**, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *Journal of Clinical Oncology*. 1999;172639-2648. doi:10.1200/jco.1999.17.9.2639 PMID: 10561337
 60. **Cobleigh MA**, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. *Journal of the American Medical Association*. 1999;2811528-1530. doi:10.1001/jama.281.16.1528 PMID: 10227323
 61. Gattuso P, Bloom K, Yaremko L, Borok R, Cobleigh M, Madsen K, Gould VE, Reddy V. Marker panel predictive of lymph node metastasis in young patients with breast carcinoma. *International Journal of Surgical Pathology*. 1998;655-60. doi:10.1177/106689699800600201 PMID: None
 62. **Cobleigh MA**. Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors.. *Cancer treatment and research*. 1998;94209-230. doi:10.1007/978-1-4615-6189-7_12 PMID: 9587690
 63. Cobleigh M. Properties of breast tumors diagnosed in women receiving HRT and cure rate projections per breast cancer stage. *Obstetrical and Gynecological Survey*. 1998;53doi:10.1097/00006254-199810001-00016 PMID: None

64. Santen RJ, Anderson T, Bardin CW, Barrett-Conner E, Black C, Borwhat M, Burger H, Clarkson T, Cobleigh M, Cosman F, Douglas MS, Dunaif A, Ford J, Ganz P, Gleason S, Goodwin P, Goss P, Green B, Gretz E, Harvey J, Hazzard W, Helzlsouer K, Jordan VC, Josse R, Kelaghan J, Kleerekoper M, Lewis J, Llewellyn-Thomas H, Loprinzi C, Mark M, Martin A, Martin H, Miesfeldt S, Moore M, Nachtigall L, New M, O'Connor A, Olsen M, Parker B, Parnes H, Perlman J, Pinkerton J, Powles T, Prior J, Pritchard K, Ragaz J, Railey E, Rumen N, Ropka M, Ross RK, Sawka C, Sellin R, Slingluff C, Swain S, Tysenhouse P, Watts N, Whamond E, Wills M. Treatment of estrogen deficiency symptoms in women surviving breast cancer. *Journal of Clinical Endocrinology and Metabolism*. 1998;83:1993-2000. doi:10.1210/jcem.83.6.4934 PMID: 9626130
65. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulskey DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the functional assessment of cancer therapy- breast quality-of-life instrument. *Journal of Clinical Oncology*. 1997;15:974-986. doi:10.1200/JCO.1997.15.3.974 PMID: None
66. **Cobleigh MA**. Hormone replacement therapy for breast cancer survivors. *Gynecological Endocrinology*. 1997;11:49-51. doi:10.3109/09513599709152581 PMID: None
67. Cobleigh M. The Colditz Article Reviewed. *ONCOLOGY*. 1997;11:1501. PMID: None
68. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL, Jablon L, **Cobleigh MA**, Hoskins K, Garber JE. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. *New England Journal of Medicine*. 1997;336:1409-1415. doi:10.1056/NEJM199705153362002 PMID: 9145677
69. Deutsch TA, **Cobleigh MA**. Tamoxifen ocular toxicity: preliminary results of a prospective observational trial. *Investigative Ophthalmology and Visual Science*. 1997;38 PMID: None
70. McCaskill-Stevens WJ, Sparano JA, Cobleigh M, Robert NJ, Baughman C, Neuberg D, Rowinsky EK, Sledge GW. Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer. *Breast Journal*. 1997;3:19-24. doi:10.1111/j.1524-4741.1997.tb00136.x PMID: None
71. Bines J, Oleske DM, **Cobleigh MA**. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. *Journal of Clinical Oncology*. 1996;14:1718-1729. doi:10.1200/JCO.1996.14.5.1718 PMID: None
72. Ghalie R, Williams SF, Valentino LA, Feingold J, Korenblit AD, Adler SS, Manson S, Pruett J, **Cobleigh MA**, Wolter J, Lincoln ST, Hartsell W, Kaizer H. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer.. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 1995;1:40-46. PMID: 9118289
73. **Cobleigh MA**, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC. Estrogen Replacement Therapy in Breast Cancer Survivors. *JAMA: The Journal of the American Medical Association*. 1995;273:621. doi:10.1001/jama.1995.03520320027033 PMID: None
74. LaFollette S, Cobleigh M. Dietary and chemoprevention strategies for breast cancer prevention. *Cancer Control*. 1995;2:218-222. PMID: None
75. Hartsell WF, Recine DC, Griem KL, **Cobleigh MA**, Witt TR, Murthy AK. Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy?. *International Journal of Radiation Oncology, Biology, Physics*. 1994;30:49-53. doi:10.1016/0360-3016(94)90518-5 PMID: 8083128
76. **Cobleigh MA**, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC. Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change. *JAMA: The Journal of the American Medical Association*. 1994;272:540-545. doi:10.1001/jama.1994.03520070060039 PMID: 8046809
77. Ghalie R, Richman CM, Adler SS, **Cobleigh MA**, Korenblit AD, Manson SD, McLeod BC, Taylor IV SG, Valentino LA, Wolter J, Kaizer H. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. *Journal of Clinical Oncology*. 1994;12:342-346. doi:10.1200/JCO.1994.12.2.342 PMID: 8113841

78. **Cobleigh MA**. Breast cancer and fenretinide, an analogue of vitamin A. *Leukemia*. 1994;8 PMID: 7808027
79. Ghalie R, Richman CM, Bender JG, McLeod BC, Lee W, Czyzewski A, Manson S, **Cobleigh MA**, Reed S, Pierre R, George S, Kaizer H. Sequential transplants using mobilized peripheral blood progenitor cells. *Journal of Clinical Apheresis*. 1994;9:176-182. doi:10.1002/jca.2920090307 PMID: 7535760
80. **Cobleigh MA**, Dowlatshahi K, Deutsch TA, Mehta RG, Moon RC, Minn F, Benson AB, Rademaker AW, Ashenurst JB, Wade JL, Wolter J. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. *Journal of Clinical Oncology*. 1993;11:474-477. doi:10.1200/JCO.1993.11.3.474 PMID: 8445423
81. Ganz PA, Bennett CL, Berek J, **Cobleigh MA**, Cohen RJ, Fabian C, Holland J, Hubbard SM, Levine MN, Love RR, Morrow M, Peters W, Skeel R. The physician as the patient's advocate. *Journal of Clinical Oncology*. 1993;11:1011-1013. doi:10.1200/JCO.1993.11.6.1011 PMID: 8501487
82. Lee KC, Schechter CB, **Cobleigh MA**, Lichtman SM, Budman DR, Donohue JH, Nagorney DM, Grant CS, Vanheerden JA, Sarr MG, Sterioff S, Farnell MB, McIlrath DC, Pemberton JH, Mucha P, Buckman RA, Pritchard KI, Sutherland DJ, Mackenzie RG, Ackerman I, Doherty MA, Catton PA, Tannock IF, Fisher B, Redmond C, Devita VT, Goldhirsch A, Gelber RD, Castiglione M. Adjuvant Therapy for Node-Negative Breast Cancer. *New England Journal of Medicine*. 1989;321:469-473. doi:10.1056/NEJM198908173210711 PMID: 2761581
83. Lad TE, Blough RR, Evrard M, Shevrin DP, **Cobleigh MA**, Johnson CM, Hange P. Phase II trial of spirogermanium in advanced non-small cell lung cancer - An Illinois Cancer Council study. *Investigational New Drugs*. 1989;7:223-224. doi:10.1007/BF00170862 PMID: 2551841
84. Shevrin DH, Lad TE, Kilton LJ, **Cobleigh MA**, Blough RR, Weidner LL, Vogelzang NJ. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: An Illinois Cancer Council study. *Investigational New Drugs*. 1989;7:251-253. doi:10.1007/BF00170869 PMID: 2477345
85. **Cobleigh MA**, Kennedy JL, Wong AC, Hill JH, Lindholm KM, Tiesenga JE, Kiang R, Applebaum EL, McGuire WP. Primary culture of squamous head and neck cancer with and without 3T3 fibroblasts and effect of clinical tumor characteristics on growth in vitro. *Cancer*. 1987;59:1732-1738. doi:10.1002/1097-0142(19870515)59:10<1732::AID-CNCR2820591010>3.0.CO;2-Q PMID: 3828946
86. **Cobleigh MA**, Hill JH, Lad TE, Shevrin DE, Applebaum EL. Phase II study of etoposide in previously untreated squamous cell carcinoma of the head and neck. *Cancer Treatment Reports*. 1987;71:321-322. PMID: 3815398
87. Fowler JE, Patel PS, Layden T, Cobleigh M, Wong A. Retroperitoneal mass and elevation of alpha-fetoprotein following lymphadenectomy and adjuvant chemotherapy for nonseminomatous testicular cancer. *Journal of Urology*. 1987;137:1216-1218. doi:10.1016/S0022-5347(17)44457-0 PMID: None
88. **Cobleigh MA**, Lindholm KM. Culture of Squamous Head and Neck Cancer on 3T3 Fibroblasts following Isokinetic Velocity Sedimentation¹. *Cancer Research*. 1986;46:6364-6368. PMID: 3779653
89. Hill JH, Rok B, Harris DM, **Cobleigh MA**. Fluorescent microscopy of hematoporphyrin derivative in the nude mouse tumor model. *Laryngoscope*. 1986;96:851-857. doi:10.1002/lary.1986.96.8.851 PMID: 2942741
90. **Cobleigh MA**, Kennedy JL. NonHodgkin's lymphomas of the upper aerodigestive tract and salivary glands. *Otolaryngologic Clinics of North America*. 1986;19:685-710. PMID: 3540797
91. Shevrin DH, McGuire WP, Lanzotti V, Krauss S, Blough R, Cobleigh M, Johnson C, Lad T, Kukla L. Phase II trial of aminothiadiazole in advanced non-small cell lung cancer. *Cancer Treatment Reports*. 1986;70:417-418. PMID: 3955556
92. **Cobleigh MA**, Hill JH, Gallagher PA, Kukla LJ, Lad TE, Shevrin DH, Applebaum EL, McGuire WP. A phase II study of adriamycin in previously untreated squamous cell carcinoma of the head and neck. *Cancer*. 1985;56:2573-2575. doi:10.1002/1097-0142(19851201)56:11<2573::AID-CNCR2820561106>3.0.CO;2-U PMID: 4052934

93. Kirkwood JM, Vera R, Fischer DS, Emstoft MS, Lutes R, Lytton B, Harris JE, Sandler S, Khandekar J, Gordon L, Bonomi P, Cobleigh M, Taylor IV SJ. A Randomized Study of Low and High Doses off Leukocyte -Interferon in Metastatic Renal Cell Carcinoma: The American Cancer Society Collaborative Trial. *Cancer Research*. 1985;45:863-871. PMID: 3881175
94. **Cobleigh MA**, Hill JH, Lindholm KM, McGuire WP. Isokinetic velocity sedimentation (IVS) on human head and neck squamous cancer (SCC H/N). *Proceedings of the American Association for Cancer Research*. 1985;VOL. 26 PMID: None
95. **Cobleigh MA**, Gallagher PA, Hill JH, Applebaum EL, McGuire WP. Growth of human squamous head and neck cancer in vitro. *American Journal of Pathology*. 1984;115:397-402. PMID: 6375391
96. Braun DP, Harris ZL, Harris JE, Sandler S, Khandekar J, Locker G, Haid M, Gordon L, Shaw J, Cobleigh M. Effect of interferon therapy on indomethacin-sensitive immunoregulation in the peripheral blood mononuclear cells of renal cell carcinoma patients. *Journal of Biological Response Modifiers*. 1983;22:251-262. PMID: 6196453
97. McGuire WP, Blough RR, **Cobleigh MA**, Johnson CM, Kukla LJ, Lad TE, Lanzotti VJ, Stiff PJ, Zawila P. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: An Illinois Cancer Council study. *Cancer Treatment Reports*. 1983;67:841-842. PMID: 6883363
98. Kaplan BH, Palmer JG, **Cobleigh MA**, Bonadonna G, Santoro A, Valagussa P, Mayer RJ. Alternating Drug Combinations for Advanced Hodgkin's Disease. *New England Journal of Medicine*. 1982;307:687-689. doi:10.1056/NEJM198209093071119 PMID: 6180317
99. Kuzur ME, **Cobleigh MA**, Greco FA, Einhorn LH, Oldham RK. Endodermal sinus tumor of the mediastinum. *Cancer*. 1982;50:766-774. doi:10.1002/1097-0142(19820815)50:4<766::AID-CNCR2820500424>3.0.CO;2-X PMID: 7093910
100. Furnas BE, Williams SD, Einhorn LH, **Cobleigh MA**. Vindesine: An effective agent in the treatment of non-small cell lung cancer. *Cancer Treatment Reports*. 1982;66:1709-1711. PMID: 7116347
101. **Cobleigh MA**, Williams SD, Einhorn LH. Phase II study of vindesine in patients with metastatic breast cancer. *Cancer Treatment Reports*. 1981;65:659-663. PMID: 7248983
102. **Cobleigh MA**, Harris JE. Quantitation of lymphocytes and t-cell subsets in patients with disseminated cancer. *Journal of the National Cancer Institute*. 1980;64:1041-1045. doi:10.1093/jnci/64.5.1041 PMID: 6966003
103. **Cobleigh MA**, Braun DP, Harris JE. Age-dependent changes in human peripheral blood B cells and T-cell subsets: Correlation with mitogen responsiveness. *Clinical Immunology and Immunopathology*. 1980;15:162-174. doi:10.1016/0090-1229(80)90028-8 PMID: 6965469
104. Braun DP, **Cobleigh MA**, Harris JE. Multiple concurrent immunoregulatory defects in cancer patients with depressed PHA-induced lymphocyte DNA synthesis. *Clinical Immunology and Immunopathology*. 1980;17:89-101. doi:10.1016/0090-1229(80)90076-8 PMID: 6447563
105. Braun DP, **Cobleigh MA**, Harris JE. Explanation for rebound-overshoot recovery of immune function in cancer patients receiving cytotoxic drugs. *Clinical Research*. 1979;27 PMID: None
106. Chowdhary M, Sen N, Chowdhary A, Usha L, **Cobleigh MA**, Wang D, Patel KR, Barry PN, Rao RD. Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination. *Advances in Radiation Oncology*. 2019;4:453-457. doi:10.1016/j.adro.2019.03.011 PMID: None

Articles not indexed by Scopus

1. Duarte Ow J, Hemu M, Yakupovich A, Bhatt P, Gaddam H, Prabhu N, Fughhi I, Cobleigh M, Tracy M, Fogg L, Okwuosa T. Influence of breast reconstruction on technical aspects of echocardiographic image acquisition compared with physician-assessed image quality. *Cardiooncology*. 2019;4:5:17 doi:doi: 10.1186/s40959-019-0052-7

Manuscripts in Press

1. Chowdhary M, Sen N, Chowdhary A, Usha L, Cobleigh M, Wang D, Patel KR, Barry PB, Rao R. Safety and Efficacy of Palbociclib and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel Combination [in review]. *Advances in Radiation Oncology*. .

Accepted Manuscripts

1. Sanja B. Turturro, Matthew S. Najor, Timothy Yung, Liam Portt, Christopher S. Malarkey, Abde M. Abukhdeir, and Melody A. Cobleigh. . Somatic loss of PIK3R1 may be sensitize breast cancer to inhibitors of the MAPK pathway [in review]. *Breast Cancer Research and Treatment*. 2019.
2. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. *Breast Cancer Research and Treatment* [in review]. .

Book Chapter

1. Rao, Ruta and Cobleigh, Melody. Optimal First-Line Treatment of Advanced HER2-Positive Breast Cancer. In: Hurvitz, Sara & McCann, Kelly, eds. *Advanced Disease* . St. Louis, Missouri: Elsevier Publisher; 2019:41-62.
2. Tower A, Rao RD, Siziopikou KP, **Cobleigh MA**, Julian TB. Anti-HER2/neu therapy in DCIS. *Ductal Carcinoma in Situ and Microinvasive/Borderline Breast Cancer*. 2015;99-108. doi:10.1007/978-1-4939-2035-8_10 PMID: None

Other Publications

1. Jamile M. Shammo, Lydia Usha, Kristin J. Richardson, Elizabeth Elliott, Summer Dewdney, Parameswaran Venugopal, Melody Cobleigh, Timothy M. Kuzel. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. *Journal of Oncology Practice*. 2019. doi:10.1200/JOP.18.00705
2. Stefan Green; Vincent (Hong) Hu; Melody Cobleigh; Jacob Rotmensch; Kelly Burgess; Lydia Usha, Lela Buckingham, PhD; Rachel Mitchell; Mark Maienschein-Cline. Somatic Variants of Potential Clinical Significance in the Tumors of BRCA Phenocopies Hereditary Cancer in Clinical Practice. 2019.

Abstracts

1. Erika Hamilton, Matthea Reinisch, Sherene Loi, Alicia Okines, Paula Pohlmann, Eva Harder Brix, Hugues Bourgeois, Belinda Yeo, Cheryl Aylesworth, Melody Cobleigh, Anthony Goncalves, Kathleen Kemmer, Rebecca Moroosse, Katherine Rak Tkaczuk, Michaela Tsai, Christine Simmons, Michael Andersson, Hatem Soliman, Michelina Cairo, Lisa Carey, David Cameron, Jorge Ramos, Wentao Feng, Mafalda Oliveira. Tucatinib vs Placebo in Combination with Trastuzumab and Capecitabine for Patients with Locally Advanced Unresectable or HER2 Positive Metastatic Breast Cancer (HER2CLIMB): Outcomes by Hormone Receptor Status. *SABCS 2020*. 2020 - Present.
2. Sandra Gomez-Perez, Rachel Barrett (Rush), Monica L Bojko (Rush), Giulia Buzzi (Rush), Amber Smith (Rush), Paula OConnor (Loyola), Joy Sclamberg (Rush), Ruta Rao (Rush), Melody Cobleigh (Rush), Cara Joyce (Loyola), Laurie Lomasney (Loyola), Vasilios Vasilopoulos (Loyola), Patricia Sheean (Loyola). Prevalence of Sarcopenia in Women with Metastatic Breast Cancer, Food and nutrition Conference and Expo (FNCE), presented October 18, 2020, Indianapolis, IN. 2020 - Present.
3. Melody A. Cobleigh,MD,1,2 Stewart J. Anderson, PhD,1,3 Kalliopi P. Siziopikou, MD, PhD,1,4 Douglas W. Arthur, MD,1,5 Thomas B. Julian, MD,1,6 Rachel Rabinovitch1,7 David S. Parda, MD,1,6 Samantha A. Seaward, MD,1,8 Dennis L. Carter, MD,1,9 Janice A. Lyons, MD,1,10 Melissa S. Dillmon, MD,1,11 Gustav Magrinat, MD,1,12 Vivek S. Kavadi, MD,1,13 Allison M. Zibelli, MD,1,14 Lavanya Tiriveedhi, MD,1,15 Matthew L. Hill, DO,1,16 Marianne K. Melnik, MD,1,17 Sushil Beriwal, MD,1,18 Eleftherios P. Mamounas, MD,1,19 Norman Wolmark, MD,1,3. Primary results of NRG Oncology / NSABP B-43: A phase III clinical trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-positive ductal carcinoma in situ resected by lumpectomy. *ASCO, LBA*, May 29, 2020. 2020 - Present.
4. Melody A. Cobleigh, Molly DiScala, Matthew S. Najor, Timothy Yung, Abde M. Abukhdeir; STAT6 expression and trastuzumab resistance in HER2+ breast cancer. *J Clin Oncol* 38: 2020 (suppl; abstr e13006), DOI 10.1200/JCO.2020.38.15_suppl.e13006. Published May, 2020. 2020 - Present.
5. Melody A. Cobleigh, Stewart J. Anderson, Kalliopi P. Siziopikou, Douglas W Arthur, Thomas B. Julian, Rachel Rabinovitch, David S. Parda, Samantha A. Seaward, Dennis L. Carter, Janice A. Lyons, Melissa S. Dillmon, Gustav Magrinat, Vivek S Kavadi, Allison M. Zibelli, Lavanya Tiriveedhi,

- Matthew L. Hill, Marianne Melnik, Sushil Beriwal, Eleftherios P. Mamounas, Norman Wolmark; Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy. *J Clin Oncol* 38: 2020 (suppl; abstr 508), DOI 10.1200/JCO.2020.38.15_suppl.508. Published May, 2020. 2020 - Present.
6. Millado, Kristen, Fogg, Lou, Ghai, Ritu, Cobleigh, Melody. Validation of the Hopkins OncotypeDx predictor. SABCs Annual Meeting, Presented as poster, December 13, 2019 in San Antonio, Texas. 2019 - Present.
 7. D.-Y. Oh, E. Hamilton, D. Hanna, M. Beeram, K.-W. Lee, Y.-K. Kang, J. Chaves, J.-Y. Lee, R. Goodwin, C. Vaklavas, S.-Y. Rha, E. Elimova, J. Mayordomo, C. Ferrario, M. Cobleigh, A. Fortenberry, G. Rowse, T. Gray, R. Lai, F. Meric Bernstam. Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumors. ESMO-Asia mini oral presentation, Singapore, 22 November 2019 . 2019 - Present.
 8. Funda Meric-Bernstam¹; Jorge Chaves²; Do-Youn Oh³; Jeeyun Lee⁴; Yoon-Koo Kang⁵; Erika Hamilton⁶; Jose Mayordomo⁷; Melody Cobleigh⁸; Christos Vaklavas⁹; Elena Elimova¹⁰; Jaffer Ajani¹; Jordi Rodon¹; Gerry Rowse¹¹; Todd Gray¹¹; Rose Lai¹¹; and Diana Hanna¹². Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer. Poster for presentation at the Triple Meeting October 2019. 2019 - Present.
 9. Funda Meric-Bernstam¹; Jorge Chaves²; Do-Youn Oh³; Jee-yun Lee⁴; Yoon Koo Kang⁵; Erika Hamilton⁶; Jose Mayordomo⁷; Melody Cobleigh⁸; Kristos Vaklavas⁹; Elena Elimova¹⁰; Jaffer Ajani¹; Jordi Rodon¹; Gerry Rowse¹¹; Todd Gray¹¹; Rose Lai¹¹; and Diana Hanna¹² . Safety and efficacy of ZW25, a HER2 targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing breast and gastroesophageal cancers. 7-12-19 to 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. . 2019 - Present.
 10. Abstract Temporary ID#: 263941, Abemaciclib with or without fulvestrant for the treatment of hormone receptor positive and HER2 negative metastatic breast cancer with disease progression following prior treatment with palbociclib. Keerthi Tamragouri, Melody Cobleigh, Ruta Rao, Published May 2019. Proceedings of The American Society of Clinical Oncology. Abstrace # e12533. 2019.
 11. Funda Meric-Bernstam, Diana Hanna, Murali Beeram, Keun-Wook Lee, Yoon-Ko Kang, Jose Chaves, Jee-Yun Lee, Rachel Goodwin, Christos Vaklavas, Do-Youn Oh, Sun-Young Rha, Elena Elimova, Jose Mayordomo, Cristiano Ferrario, Melody Cobleigh, Allison Fortenberry, Gerry Rowse, Todd Gray, Rose Lai and Erica Hamilton. The safety, efficacy and biomarker results of the HER2-targeted bi-specific antibody ZW25 in HER2-expressing solid tumors. Proceedings of The European Society of Modical Oncology 2019. 2019.
 12. Abde M. Abukhdeir, Matthew S. Najor, Satnam Brar, Sanja Turturro, Liam Portt, Timothy Yung, Melody A. Cobleigh. Loss of NF1 in Breast Cancer Activates Multiple Pathways in Breast Cancer, 2018 2016 ASCO Annual Meeting Temp Abstract #223705, submitted February 2018. 2018.
 13. Jamile M. Shammo, Lydia Usha, Kristin J. Richardson, Elizabeth Elliott, Summer Dewdney, Parameswaran Venugopal, Melody A. Cobleigh, Timothy Kuzel, Olaparib-Induced Severe Folate Deficiency in Women with Relapsed Ovarian Cancer: First Report and Case Series. Temporary Abstract #224975, submitted February 2018. 2018.
 14. Melanie Jean Clark, James Coggan, James J. Dignam, Ruta D. Rao, Lydia Usha, Katherine Kabaker, Mark McCarthy, Eric Finkelstein, Melody A. Cobleigh. Cost Effectiveness Analysis of Oncotype Dx Testing in Patients with Synchronous Unilateral Primary Breast Cancer. Temporary Abstract #223189, submitted February 2018. 2018.
 15. Shammo JM¹, Usha L, Elliott E, Richardson K, Dewdney S, Venugopal P, Cobleigh M, and Kuzel TM. First report of severe folate deficiency in women treated with olaparib for relapsed ovarian cancer. Published online-only on the ASH abstracts site on December 8, 2017, part of the permanent ASH and Blood abstracts archive. 2017.

16. Mohammad Jahanzeb,¹ Debu Tripathy,² Sara A. Hurvitz,³ Joyce O'Shaughnessy,⁴ Ginny Mason,⁵ Denise A. Yardley,⁶ Adam Brufsky,⁷ Hope S. Rugo,⁸ Melody Cobleigh,⁹ Sandra M. Swain,¹⁰ Laura Chu,¹¹ Vincent Antao,¹¹ Bongin Yoo,¹¹ Peter A. Kaufman¹². First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry. Poster presentation, ESMO Published online August 31, 2017. 2017.
17. Peter A. Kaufman, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Melody Cobleigh, Sandra M. Swain, Debu Tripathy, Laura Chu, Vincent Antao, Bongin Yoo, Mohammad Jahanzeb. Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry. Poster presentation, ESMO Published online August 31, 2017. 2017.
18. Burgess, Usha, Cobleigh, Gattuso, etc. Hereditary Diffuse Gastric Cancer and Lynch Syndromes in a BRCA1/2 negative breast cancer patient. Accepted for publication 7-8-17 Breast Cancer Research and Treatment. 2017.
19. Ma C, **Cobleigh MA**, Cell-free tumor DNA (ctDNA) sequencing as a strategy for ERBB2 (HER2) mutation (HER2mut) screening and neratinib response monitoring in patients (pts) with HER2 non-amplified metastatic breast cancer (MBC). AACR 2017, Oral presentation. 2017.
20. Abukhdeir AM, Turturro SB, Najor MS, Brar SS, **Cobleigh MA**; Mutations in PIK3R1 activate multiple pathways in breast cancer, Presented at The San Antonio Breast Cancer Symposium, December 12, 2016. 2016.
21. Cobleigh M, Yardley DA, Brufsky A, Rugo H, Swain S, Kaufman PA, Tripathy D, Mayer M, Hurvitz S, O'Shaughnessy J, Mason G, Chu L, Antao V, Beattie M, Yoo B, Jahanzeb M. Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR- HER2+ disease from the SystHERs registry. Presented at The San Antonio Breast Cancer Symposium, December 12, 2016. Cancer Research. 77. P5-08. 10.1158/1538-7445.SABCS16-P5-08-27. 2016.
22. Jahanzeb M, Tripathy D, Rugo H, Swain S, Kaufman PA, Mayer M, Hurvitz S, O'Shaughnessy J, Mason G, Yardley DA, Brufsky A, Chu L, Antao V, Beattie M, Yoo B, Cobleigh M. Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry. Presented at The San Antonio Breast Cancer Symposium, December 12, 2016. 2016.
23. Sara Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope Rugo, Sandra Swain, Peter Kaufman, Debu Tripathy, Musa Mayer, Laura Chu, Bongin Yoo, Mary S. Beattie, Melody Cobleigh. Central Nervous System Metastases at Diagnosis in Patients With HER2-Positive metastatic breast cancer: Baseline Characteristics, HER2-Targeted Treatments and Clinical Outcomes From the SystHERs Registry. Presented at The San Antonio Breast Cancer Symposium, December 12, 2015, P6-17-01. Cancer Res February 15 2016 76 (4 Supplement) P6-17-01-P6-17-01; DOI:10.1158/1538-7445.SABCS15-P6-17-01. 2016.
24. Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Mark D. Pegram, Kimberly Blackwell, Philippe L. Bedard, Daniel F. Hayes, Matthew P. Goetz, Polly Ann Niravath, Christy Ann Russell, Debu Tripathy, Melody A. Cobleigh, Andres Forero, Timothy J. Pluard, Carey K. Anders, Caroline Bumb, Michael Naughton, Hussam Al-Kateb, Matthew James Ellis; Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC). Poster discussion at the 2016 ASCO Annual Meeting. J Clin Oncol 34, 2016 (suppl; abstr 516). 2016.
25. Abukhdeir, AM*; Najor, M; Turturro, S; Pergande, M; Borgia, J; Khalak, H; Cobleigh, M Abstract Number: 1159, Abstract Title: Elucidating molecular resistance to trastuzumab using next generation sequencing in isogenic cell models Program Number: P5-05-07. Presented at SABCS Dec, 2014. Cancer Res May 1 2015 75 (9 Supplement) P5-05-07-P5-05-07; DOI:10.1158/1538-7445.SABCS14-P5-05-07. 2015.
26. Debu Tripathy, Adam Brufsky, Melody Cobleigh, Mohammad Jahanzeb, Peter Kaufman, Ginny Mason, Musa Mayer, Joyce O'Shaughnessy, Hope S. Rugo, Sandra M. Swain, Denise A. Yardley, Mary Beattie, Bongin Yoo, Sara Hurvitz. Increasing proportion of de novo compared with recurrent

- HER2-positive metastatic breast cancer: early results from the Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry Study. Presented at SABCS Dec 2014. *Cancer Res* May 1 2015 75 (9 Supplement) P3-07-14; DOI:10.1158/1538-7445.SABCS14-P3-07-14. 2015.
27. Sara Hurvitz, Mohammad Jahanzeb, Peter Kaufman, Ginny Mason, Musa Mayer, Hope Rugo, Debu Tripathy, Sarika Ogale, Anthony Masaquel, Bongin Yoo, Mary Beattie, Melody Cobleigh. Patient-Reported Outcomes (PROs) From the Systemic Therapies for HER2-Positive Metastatic Breast Cancer (MBC) Registry Study (SystHERs): Eliciting the Patient Experience. Presented at ASCO-QCS 2014. *J Clin Oncol* 32, 2014 (suppl 30; abstr 286). 2014.
 28. Cobleigh, Melody A. and Anderson, Stewart J. and Julian, Thomas B. and Siziopikou, Kalliopi P. and Arthur, Douglas W. and Rabinovitch, Rachel and Zheng, Ping and Mamounas, Eleftherios P. and Wolmark, Norman, NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx). *J Clin Oncol* 31, (suppl; TPS666, 2013) Poster presentation . 2013.
 29. Michiels, Stefan and Pugliano, Lina and Grun, Delphine and Barinoff, Jana and Cameron, David A. and Cobleigh, Melody A. and Di Leo, Angelo and Johnston, Stephen R. D. and Gasparini, Giampietro and Kaufman, Bella and Marty, Michel E. and Nekljudova, Valentina and Paluch-Shimon, Shani and Penault-Llorca, Frederique and Slamon, Dennis J. and Vogel, Charles L. and Von Minckwitz, Gunter and Buyse, Marc E. and Piccart-Gebhart, Martine J. Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. *J Clin Oncol* 31(suppl; p 610, 2013) Poster presentation. 2013.
 30. B. Tabesh, L. Usha, D. Oleske, J. Canar, R. Borchik, Y. Christmas, M.A. Cobleigh; Clinical characterization of a tissue repository of high-risk breast cancer patients. *Proc Am Assoc Clin Oncol*, 21:2002, Abstract 2012. 2012.
 31. Dan Lu, Sandhya Girish, Christine Gao, Bei Wang, Joo-Hee Yi, Ellie Guardino, Meghna Samant, Melody Cobleigh, Mothaffar Rimawi, Pier Franco Conte, Jin Jin. Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates. Submitted to SABCS, 2012. 2012.
 32. Melody A. Cobleigh, Stewart J. Anderson, Thomas B. Julian, Kalliopi P. Siziopikou, Douglas W. Arthur, Rachel Rabinovitch, Ping Zheng, Eleftherios P Mamounas, Alice Marie Luknic, Robert J. Behrens, Luis Chu, Nick C. Leasure, James Norman Atkins, Jonathan Polikoff, Thomas E. Seay, R Dirk Noyes, Philip J. Stella, Wortia J. McCaskill-Stevens, Norman Wolmark. A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx): NSABP B-43. *J Clin Oncol* 30, 2012 (suppl; abstr TPS657) . 2012.
 33. Palak Desai, Eduardo Braun, Irene Dehghan-Paz, Paolo Gattuso, Jeff Canar, Melody A. Cobleigh; Synchronous bilateral breast cancer (SBBC): Concordance of receptor status between right and left breast. *J Clin Oncol* 30, 2012 (suppl; abstr 572). 2012.
 34. Estrogen Receptro Status in the Herceptin (trastuzumab) Clinical Trials: Incidence and Relation to Clinical Benefit. Presented. Mass R, Cobleigh M, Vogel C, Slamon D on behalf of the Herceptin Multinational Investigators Group. *Breast Cancer Res and Treat* 69:2001 Abstract 522. 2011.
 35. K. B. Kabaker, J. Canar, R. D. Rao, M. A. Cobleigh. Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer (BC). *J Clin Oncol* 29: 2011 (suppl; abstr 620) . 2011.
 36. K. P. Siziopikou, M. A. Cobleigh, S. J. Anderson, T. B. Julian, D. W. Arthur, P. Zheng, E. P. Mamounas, E. R. Pajon, R. J. Behrens, L. Chu, N. C. Leasure, J. N. Atkins, J. Polikoff, T. E. Seay, W. J. McCaskill-Stevens, R. Rabinovitch, N. Wolmark; Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43. *J Clin Oncol* 29: 2011 (suppl; abstr 588). 2011.
 37. Rao, RD, Siziopikou KP, **Cobleigh MA**. A phase II open-label trial to evaluate the efficacy and toxicity

- of erlotinib in women with metastatic, hormone receptor-negative, and HER2-negative breast cancer. *J Clin Oncol* 29, 2011 (suppl 27; abstr 296). Poster presentation at ASCO 2011 Breast Cancer Symposium. 2011.
38. B. J. Klencke, S. Bhattacharya, M. K. Samant, J. R. Gralow, M. N. Dickler, M. A. Cobleigh, E. A. Perez, T. N. Shenkier, N. E. Davidson, K. D. Miller. Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 1036). 2008.
 39. M. A. Cobleigh, K. L. Griem, K. P. Siziopikou. Long term disease-free survival after stopping trastuzumab in trastuzumab-sensitive metastatic breast cancer patients treated with local-regional therapy. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 11542). 2008.
 40. Siziopikou KP, Gingell DC, Proussaloglou K, **Cobleigh MA**. Basal subtype and EGFR expression in breast carcinomas; evidence of racial differences. *Breast Cancer Res and Treatment* 94:Supplement Abstract [3050] 2006. 2006.
 41. Wagner LI, Wang M, Miller K, Davidson NE, Gralow J, Dickler M, Cobleigh M, Perez E, Shenkier T, Cella D. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the eastern cooperative oncology group (ECOG) study E2100. *Breast Cancer Res and Treatment* 94:Supplement Abstract [5078] 2006. 2006.
 42. K. D. Miller, H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, M. D. Pegram, P. D. Eisenberg, M. Collier, B. J. Adams, C. M. Baum. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) Accepted for presentation. *Proc Am Assoc Clin Oncol*, 24:2005, Abstract 563. 2005.
 43. Miller KD, Burstein HJ, Elias AD, Rugo HS, **Cobleigh MA**, Wolff AC, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC). *Breast Cancer Res and Treatment* 94:Supplement Abstract [1066] 2005. 2005.
 44. Miller KD, Wang M, Gralow J, Dickler M, **Cobleigh MA**, Perez EA, Shenkier TN, Davidson NE A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). *Breast Cancer Res and Treatment* 94:Supplement Abstract [3] 2005 . 2005.
 45. KP Siziopikou, R Ariga, KE Proussaloglou, P Gattuso, C Valandez, M Cobleigh. The basal-like subtype of breast carcinomas represents the group of breast carcinomas that may benefit from EGFR-targeted therapies. Accepted for presentation at USCAP 9/04. 2004.
 46. Siziopikou KP, Ariga R, Proussaloglou K, Forbes D, Valadez C, Gattuso P, Cobleigh M. The challenging Er-negative/PR-negative/HER2-negative patient; a promising candidate for EGFR targeted therapy? Accepted for presentation at SABCS 6/04. 2004.
 47. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D. Randomized phase III Study of Trastuzumab, Paclitaxel and Carboplatin versus trastuzumab and paclitaxel in women with HER2-Overexpressing Metastatic Breast Cancer. Accepted for presentation. *Proc Am Assoc Clin Oncol*, 23:2004, Abstract 573. 2004.
 48. Cobleigh M, Borchik R, Tabesh B, Bitterman P, Mosquera J, Baker J, Cronin M, Liu M, Walker M, Shak S. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: Results using a new high throughput RT-PCR assay on paraffin-embedded tumor tissue. Accepted for presentation. *Proc Am Assoc Clin Oncol*, 22:2003, Abstract 3415. 2003.
 49. K. J. Hillan, H. K. W. Koeppen, P. Tobin, T. Pham, T. H. Landon, K. D. Miller, F. A. Holmes, M. A. Cobleigh, J. D. Reimann, V. K. Langmuir. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Accepted for presentation. *Proc Am Assoc Clin Oncol*, 22:2003, Abstract 766. 2003.
 50. Miller KD, Saphner T, Waterhouse D, Chen Tai-Tsang, Rush-Taylor A, Sparano J, Wolff A, Cobleigh M, Galbraith S, Sledge GW. A randomized pilot trial of BMS-275291 in patients with early stage

- breast cancer. Accepted for presentation, Proc Am Assoc for Cancer Res, 44: abstract 6353, 2003. 2003.
51. Miller KD, Rugo HS, **Cobleigh MA**, Marcom PK, Chap L, Holmes FA, Fehrenbacher L, Overmoyer BA, Reimann JD, Vassel AV, Langmuir VK. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res and Treat 76, Supplement 1, December 2002 Abstract 36. . 2002.
 52. Robert N, Slamon D, Leyland Jones B, Belt R, Ilegbodun D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Asmar L. Phase III Comparative Study Of Herceptin And Taxol With And Without Carboplatin In HER2-Positive Patients With Advanced Breast Cancer. Breast Cancer Res and Treat 76, Supplement 1, December 2002 Abstract 35. 2002.
 53. Winer E, Cobleigh M, Dickler M, Miller K, Fehrenbacher L, Jones C, Justice R. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res and Treat 76, Supplement 1, December 2002 Abstract 445. . 2002.
 54. Virginia K Langmuir, Melody A Cobleigh, Roy S Herbst, Eric Holmgren, Herbert Hurwitz, Fairouz Kabbinavar, Kathy Miller, William Novotny, Successful long-term therapy with bevacizumab (AvastinTM) in solid tumors. Presented. Proc Am Assoc Clin Oncol, 21:2002, Abstract 32. 2002.
 55. Bolton MG, Cobleigh M, Vogel C, Slamon D. Estrogen Receptor (ER) Status Does Not Predict Benefit to Trastuzumab (Herceptin): a Review of the Herceptin Clinical Trials Experience. Proc Am Assoc Clin Oncol, 20:2001, Abstract 172. 2001.
 56. Gradishar WJ, O'Neill A, Cobleigh M, Goldstein LJ, Davidson NE. A Phase II Trial with Antisense Oligonucleotide ISIS 3521/Cgp 64128a in Patients (Pts) with Metastatic Breast Cancer (MBC): ECOG Trial 3197. Proc Am Assoc Clin Oncol, 20:2001, Abstract 171. 2001.
 57. Malhotra R, Canar J, Harris D, Borchik R, Christmas Y, Oleske D, **Cobleigh MA** Race, Prognostic Factors and Long Term Follow-Up in High Risk Breast Cancer. Proc Am Assoc Clin Oncol, 20:2001, Abstract 1824. 2001.
 58. Phase II dose escalation trial of Avastin (bevacizumab; rhuMab VEGF) in women with previously treated metastatic breast cancer (MBC). Cobleigh M, Miller K, Sledge G, Reimann J, Vasses A, Novotny W, Langmuir VK. Presented. Breast Cancer Res and Treat 69:2001 Abstract 520. 2001.
 59. Vogel C, Cobleigh M, Tripathy D, Mass R, Murphy M, Stewart SJ. Superior Outcomes with Herceptin (trastuzumab) (H) in Fluorescence in Situ Hybridization (FISH)-Selected Patients. Proc Am Assoc Clin Oncol, 20:2001, Abstract 86. 2001.
 60. **Cobleigh MA**, Gray R, Graham M, Norton L, Martino S, Budd GT, Ingle JN, Davidson NE, Wood WC. Fenretinide (FEN) vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group Phase III Intergroup trial (EB193, INT 0151). Proc Am Assoc Clin Oncol, 19:86a, 2000, Abstract 328. 2000.
 61. Miller KD, Gradishar WJ, Schuchter LM, Sparano JA, **Cobleigh MA**, Robert NU, Guiney P, McDonald AL, Rasmussen H & Sledge GW. A randomized phase II pilot trial of adjuvant marimastat (MAR) in patients with early breast cancer. Proc Am Assoc Clin Oncol, 19:96a, 2000, Abstract 369. 2000.
 62. Sledge G, Miller K, Novotny W, Gaudreault J, Ash M, Cobleigh M. A phase II trial of single-agent rhuMab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc Am Assoc Clin Oncol, 19:3a, 2000, Abstract 5c. 2000.
 63. Starr A, Bloom K, Oleske D, **Cobleigh MA**. Comparison of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in determining HER-2/neu status in breast cancer patients. Proc Am Assoc Clin Oncol, 19:662a, 2000, Abstract 2610. 2000.
 64. Vogel C, Cobleigh M, Tripathy D, Harris L, Fehrenbacher L, Slamon D, Ash M, Novotny W, Stewart S, Shak S. First-line non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-her2 antibody), Proc Am Assoc Clin Oncol,

- 19:71a, 2000, Abstract 275. . 2000.
65. Cobleigh M. Herceptin is active as a single agent in women with metastatic breast cancer overexpressing HER2. ECCO 10 European J Cancer. S315, Abstract #1264, 1999. 1999.
 66. Gradishar W, Cobleigh M., Sparano J, Schuchter L, Zaring D, Rasmussen H. A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer. Accepted for presentation and publication, Proc Am Assoc Clin Oncol, 18:125a, 1999, Abstract 476. 1999.
 67. Lieberman G, Burchmore M, Ferhenbacher L, Cobleigh M, Health related quality of life of patients treated with Herceptin (trastuzumab) as a single agent. Accepted for presentation and publication, Proc Am Assoc Clin Oncol, 18:417a, 1999, Abstract 1613. 1999.
 68. Chopra HK, Sivaraman S, Baker K, Gupta-Burt S, Markus, E, Coon J, Cobleigh M, Cass L, Spaulding D, Venugopal P, Preisler HD. Determination of labeling index (LI) by in situ hybridization (ISH) for histone H3 mRNA in locally advanced breast cancer, correlation with clinical outcome. Submitted to the San Antonio Breast Cancer Symposium, May 1998. 1998.
 69. Cobleigh M, Tripathy D, Vogel C, Robert N, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G & Slamon D. Efficacy and safety of Herceptin (Recombinant humanized anti-her2 antibody) as a single agent in 222 women with her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Accepted for publication and presentation, Proc Am Assoc Clin Oncol 17: A376, p97a, 1998. 1998.
 70. Gradishar W, Sparano J, Cobleigh M, Kennedy J, Schuchter L, Wicks J & Rasmussen H. A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer. Accepted for publication Proc Am Assoc Clin Oncol 17: A548, P144Aa 1998. 1998.
 71. Norlock FE, **Cobleigh MA**, Oleske DM. Hormone replacement therapy use correlates with high S-phase in estrogen receptor-positive primary human breast cancer. Accepted for publication and presentation, Proc Am Assoc Clin Oncol 17: A420, p109a, 1998. 1998.
 72. Couch F, DeShano M, Blackwood M, Calzone K, Stopfer J, Rebbeck T, Jablon L, Garber J, Cobleigh M, Hoskins K and Weber B. Incidence of germline BRCA1 mutations in a spectrum of hereditary breast cancer families. Proc Am Assoc for Cancer Res. 38:244 #1641, 1997. 1997.
 73. Deutsch TA, **Cobleigh MA** Tamoxifen ocular toxicity: Preliminary results of a prospective observational trial. Investigative Ophthalmology & Visual Science. 38:S427, Abstract 2018-B811, 1997. . 1997.
 74. Gattuso P, Bloom K, Yaremko L, Borok R, Cobleigh M, Reddy V. Prognostic predictors of lymph node metastasis in young patients with breast carcinoma. Proc 86th ann meeting of the United States and Canadian Academy of Pathology. Modern Pathol 10:19A, 1997. (Accepted for presentation and publication). 1997.
 75. Olopade OJ, Cmmings S, Malone D, Baker P, Schumm P, Mumby P, Chapman D, Cobleigh M, Fine B, Esserman L, Shattuck-Eidens D, Oliphant A, Ward B & Luce M. Acceptance of BRCA1/BRCA2 testing is high among cancer patients from high-risk families. Accepted and presented ASCO, Proc Am Assoc Clin Oncol 16: A1923, 1997. 1997.
 76. Reddy V, Gattuso P, Bloom KJ, Yaremko L, Cobleigh M, Thompson K, Nagy S, Borok R & Gould VE. Predictors of lymph node metastasis in T1 breast cancer. Submitted to the United States and Canadian Academy of Pathology 1997. 1997.
 77. Soble MB, Oleske DM, **Cobleigh MA**, HER-2/c-erbB2 (HER-2) overexpression is a biomarker of tamoxifen resistance in breast cancer. Accepted and presented Am Assoc Soc Clin Oncol, Proc Am Assoc Clin Oncol 16: A493, 1997. 1997. 1997.
 78. Wood NB, Kluskens LF, Oleske DM, Gattuso P, Chapman DD, Witt TR & Cobleigh, MA. Intermediate markers for breast cancer development in benign tissue from women with breast cancer. Accepted and presented. Proc Am Assoc Cancer Res 38:236 #1591, 1997. 1997.
 79. Brady MJ, Cella DF, Mo F, Bonomi AE, Lloyd SR & **Cobleigh MA** Reliability and validity of the

- function assessment of cancer therapy-breast (FACT-B) quality of life instrument. Fourth intl conf of behavioral med, 1996. 1996.
80. Kudelka AM, Black SR, Easington C, Cobleigh M, Parrillo JE & Hollenberg SM. Effects of tamoxifen and premature menopause on endothelium-dependent brachial artery vasodilatation in women treated for breast cancer. Proc Am College of Cardiology, 1996. 1996.
 81. M.A. Cobleigh, S. Siddiqui, DM Oleske & DL Roseman. Case-control study of tumor estrogen receptor status in women diagnosed with breast cancer while using hormone replacement therapy (current-users) vs. those never having used hormone replacement therapy (never-users). Proc Am Assoc Clin Oncol 15: A57, 1996. (Accepted for presentation and publication). 1996.
 82. M.A. Cobleigh, S. Siddiqui, DM Oleske & DL Roseman. Case-control study of tumor S-phase status in women diagnosed with breast cancer while using hormone replacement therapy (current-users) vs. those never having used hormone replacement therapy (never-users). Proc Am Assoc for Cancer Res 37:203, 1388A 1996. (Accepted for presentation and publication). 1996.
 83. Wood NB, Kluskens LF, Oleske DM, Gattuso P, Chapman DD, Witt TR & Cobleigh, MA. Intermediate Markers for Breast Cancer Development in Benign Tissue from women with Breast Cancer. Proc Am Assoc for Cancer Res 37:203, 1388A 1996. (Accepted for presentation and publication). 1996.
 84. **Cobleigh MA**, Bines J, Harris D, Lincoln ST, LaFollette S, Wolter JM. Amenorrhea following adjuvant chemotherapy for breast cancer. Proc Am Assoc Clin Oncol 14:A158, 1995. (Accepted for presentation and publication). 1995.
 85. **Cobleigh MA**, Oleske DM, Nickerson T & Pollak M. Serum IGF-I levels in stage IV breast cancer treated with tamoxifen (tam) and fenretinide (fen). Proc Am Assoc for Cancer Res, 1995. (Accepted for presentation and publication). 1995.
 86. JC Haupt , MA Cobleigh, JM Wolter, K Dowlatshahi, D Recine & W Knudson. Miniaturization of an assay for hyaluronan in breast biopsies. Proc Am Assoc Clin Oncol 14.: A159, 1995. (Accepted for presentation and publication)). 1995.
 87. Barnicle MM, Goodman M, Purl SE, Blendowski C, Lydon J, Stewart IE & **Cobleigh MA**. Pleural access port: A creative alternative to repeated thoracentesis. Oncology Nursing Forum 21:381; 302A, 1994. Accepted for presentation and publication. 1994.
 88. **Cobleigh MA**, Bines J, Lincoln ST, Wolter JM. Amenorrhea following adjuvant chemotherapy for breast cancer. Proc Am Assoc Clin Oncol 13:A55, 1994. Accepted for presentation and publication. 1994.
 89. Kaizer H, Ghalie R, Valentino L, Feingold J, Manson S, Pruett J, **Cobleigh MA** & Wolter JM Sequential peripheral blood progenitor cell (pbpc) transplants for patients with metastatic breast cancer. J Cellular Biochem Supplement 18B, 1994, p 101, Ab G515. 1994.
 90. Turner DA, Wang JZ, Witt TR, Economou SG, Staren E, Bloom KJ, **Cobleigh MA**. Functional images from dynamic, contrast-enhanced, 3DFT MR images for the detection of breast cancer. 79th Scientific Assembly and Annual Meeting of the Radiological Society of North America, November 28 - Dec 3, 1993. 1993.
 91. Ghalie R, Valentino L, Richman C, Adler S, Korenblit A, Cobleigh M, Wolter J & Kaizer H. High-dose chemotherapy and autologous bone marrow transplantation (ABMT) for metastatic breast cancer. 22nd Annual meeting of the international society for experimental hematology, 22-26 August, 1993, Rotterdam, The Netherlands. 1993.
 92. **Cobleigh MA** and Kaplan EH. Effect of methotrexate, 5-fluorouracil and leucovorin (M TO F) adjuvant chemotherapy for breast cancer on menstruation. Proc Am Soc Clin Oncol 12:73, abst #95, 1993. Accepted for presentation and publication. 1993.
 93. MA Cobleigh, S Lincoln, M Mullane, AB Benson, F Minn, Phase I/II trial of tamoxifen (tam) + fenretinide (4HPR) in stage IV, receptor-positive, previously-untreated breast cancer. Breast Cancer Res Treat 21: 1993. Accepted for presentation and publication . 1993.
 94. Sledge G, Sparano J, McCaskill-Stevens W, **Cobleigh MA**, Robert N, Baughman C, Neuberg D,

- Rowinsky E. Pilot trial of alternating taxol and adriamycin for metastatic breast cancer. Submitted for presentation, Proc Am Soc Clin Oncol 12:71 Abst #85, 1993. 1993.
95. Sledge GW, Robert N, Goldstein LJ, Sparano J, Cobleigh M, Baughman C, Neuberg D, Rowinsky E. Phase I trial of adriamycin (A) + taxol (T) in metastatic breast cancer (MBC). The European J Cancer 29A Supplement 6:S81; #421, 1993. (Accepted for presentation and publication). 1993.
 96. Turner DA, Wang JZ, Economou SG, **Cobleigh MA**, Bloom KJ, Witt TR, Staren E. Functional images from dynamic, contrast-enhanced, 3DFT MR images for the detection of breast cancer. Proc Soc Magnetic Resonance in Medicine. 1:116, 1993. 1993.
 97. **Cobleigh MA** and Kaplan EH. Effect of methotrexate, 5-fluorouracil and leucovorin (M TO F) adjuvant chemotherapy for breast cancer on menstruation. Breast Cancer Res and Treat 23:145 Abst #60, 1992. Accepted for presentation and publication. 1992.
 98. **Cobleigh MA** and Kaplan EH. Effect of methotrexate, 5-fluorouracil and leucovorin (M TO F) adjuvant chemotherapy for breast cancer on menstruation. Breast Cancer Res and Treat 23:145 Abst #60, 1992. Accepted for presentation and publication. 1992.
 99. Hartsell WF, Recine DC, Griem KL, **Cobleigh MA**, Witt TR & Murthy AK. Should multifocality be an absolute contraindication to the use of breast conserving therapy? Int J Rad Oncol Biol Phys 24: Suppl p 260, 1992. 1992.
 100. **Cobleigh MA**, Dowlat K, Minn F, Benson A, Rademaker A, Ashenhurst J, Wade J, Wolter J. Phase I trial of tamoxifen with or without fenretinide, an analogue of vitamin A, in patients with metastatic breast cancer. Breast Cancer Res Treat 19: 1991. Accepted for presentation and publication . 1991.
 101. Ghalie R, Richman C, **Cobleigh MA**, Korenblit A, Adler S, Valentino L, Owens A, Kaizer H. Bone marrow transplantation with high-dose thiotepa, cyclophosphamide, and cisplatin (TCP) for metastatic breast cancer. Breast Cancer Res Treat; 19:161, 1991. Accepted for presentation and publication. 1991.
 102. Shevrin DH, Lad TE, Kilton LJ, **Cobleigh MA**, Vogelzang NJ, Blough RR & Weidner LL. Phase II trial of fludarabine phosphate in advanced renal cell cancer. Proc Am Soc Cancer Res. 7:124, Abstract #477, 1988. 1988.
 103. **Cobleigh MA**, Kennedy JL, Langenberg PW, Lindholm KM and Hill JH. Comparison of Benign and Malignant Head and Neck Keratinocyte Morphology Before and After Primary Culture. Proc Am Assoc for Cancer Res. Vol. 28, Abstract #127, 1987. Accepted for presentation and publication. 1987.
 104. **Cobleigh MA**, Hill JH, Lindholm KM, Kennedy JL and Langenberg PW. Isokinetic Velocity Sedimentation (IVS) of Human Head and Neck Squamous Cancer (SCC H/N). Proceed. of the American Assoc. for Cancer Res., Vol 27, #118, 1986. Accepted for presentation and publication . 1986.
 105. Hutson P, Evrard M, **Cobleigh MA**, Lad T, McGuire WP, Cichock G. Pharmacokinetic and Pharmacodynamic Studies of Spirogermanium (SG) in Advanced Non-small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 5:38, #149, 1986. 1986.
 106. **Cobleigh MA**, Hill JH, Lindholm KL, McGuire WP. Isokinetic velocity sedimentation (IVS) of human head and neck squamous cancer (SCC H/N). Proc Amer Assoc for Cancer Res. 26:22, #87, 1985. Accepted for presentation and publication. 1985.
 107. **Cobleigh MA**, Wong AC, Hill JH, McGuire WP. Growth of squamous carcinoma of the Head and Neck with and without 3T3 fibroblasts. Presented at The International Conference on Head & Neck Cancer, July, 1984 meeting. Published in Head and Neck Cancer, Chretien, ed. Mosby 1985. 1985.
 108. Evrard M, McGuire WP, **Cobleigh MA**, Johnson C, Blough R, Rose C, Park H, Lad T & Kukla L. Phase II study of spirogermanium (SG) in non-small cell lung cancer (NSCLC). Proc Amer Soc Clin Oncol. 4:184, #C720, 1985. 1985.
 109. **Cobleigh MA**, Wong A, McGuire WP. In vitro culture of squamous carcinoma of the head and neck. Proc Amer Assoc for Cancer Res. 25: 27, #103, 1984. Accepted for presentation and publication. 1984.

110. Shevrin D, McGuire WP, Lanzotti V, Krauss S, Blough R, **Cobleigh MA**, Johnson C, Lad TE, Kukla LJ. Phase II trial of aminothiadiazole (ATDA) in advanced non-small cell lung cancer (NSCLC). Proc Amer Soc Clin Oncol. 3:214, #C837, 1984. 1984.
111. **Cobleigh MA**, Gallagher PA, McGuire WP, Seligsohn R, Hill JH, Winker, M and Applebaum, E. Culture of squamous cell carcinoma of the head and neck (H/N) in the human tumor clonogenic assay (HTSCA). Proc Amer Assoc Cancer Res. 24: 313, #1240, May, 1983. Accepted for presentation and publication. 1983.
112. McGuire WP, Blough RM, **Cobleigh MA**, Johnson CM, Kukla LJ, Lad TE, Lanzotti VJ, Stiff PJ, Zawila P. Phase II trial of bisantrene (B) in unresectable non-small cell lung cancer. Proc Amer Assoc Clin Oncol. 2:185, #C- 722, 1983. . 1983.
113. **Cobleigh MA**, Benson M, Einhorn LH, and Rohn R. Suppression of immune response in peripheral blood mononuclear cells (PBMC) of testicular cancer patients. Proc. Amer Assoc Clin Oncol 22: 377, #C-177, 1981. 1981.
114. Braun DB, **Cobleigh MA**, and Harris, J. The "Rebound-overshoot" phenomenon: a consequence of selective cytotoxic drug effect on Immunoregulatory suppressor mechanisms. Proc Amer Soc Clin Oncol. 21: 373, #C-214, 1980. 1980.
115. **Cobleigh MA**, Williams SD & Einhorn LH. Vindesine, a phase II study in patients with refractory metastatic breast cancer. Proc Int Vinca Alkaloid Symposium -- Vindesine. Eds W. Brade, Gagel GA. S. Karger, p 176, 1980. 1980.
116. Melody A. Cobleigh, Stewart J. Anderson, Thomas B. Julian, Kalliopi P. Siziopikou, Douglas W. Arthur, Rachel Rabinovitch, Ping Zheng, Eleftherios P Mamounas, Alice Marie Luknic, Robert J. Behrens, Luis Chu, Nick C. Leasure, James Norman Atkins, Jonathan Polikoff, Thomas E. Seay, R Dirk Noyes, Philip J. Stella, Wortia J. McCaskill-Stevens, Norman Wolmark;.
117. Reddy V, Gattuso P, Bloom KJ, Yaremko L, Cobleigh M, Thompson K, Nagy S, Borok R & Gould VE. Predictors of lymph node metastasis in T1 breast cancer. Modern Pathology 11(1):page 26A, abstract # 132.